Schizophrenia News and Research

Latest Schizophrenia News and Research

UGA researchers identify biological markers for mental disorders

A team of researchers led by faculty at the University of Georgia has identified a number of biological markers that make it possible to classify mental disorders with greater precision. Their findings, published today in the American Journal of Psychiatry, may one day lead to improved diagnostics and treatments for those suffering from mental illness.

9 Dec 2015

New drug therapies that target glutamate pathway may be effective for subgroups of patient with schizophrenia

Mounting evidence indicates that disturbances in the brain's glutamate pathway contribute to symptoms of schizophrenia. Thus, the glutamate pathway has become the target of a number of new drug therapies. Findings published in the journal Biological Psychiatry suggest that at least one of these drugs may be an effective treatment for individuals in the early course of the illness.

9 Dec 2015

Lawson scientists develop commercial imaging product for PET/MRI scanners

Scientists at Lawson Health Research Institute, in collaboration with Ceresensa Inc., have produced the first commercial imaging product available in the world for PET/MRI scanners. The novel PET-transparent MRI head coil provides unparalleled images to advance the study, diagnosis and treatment of a wide range of diseases.

9 Dec 2015

People exiting prison or jail get access to health services

With the expansion of Medicaid under the Affordable Care Act, an entire new population is eligible for government health care: low-income men.

8 Dec 2015

DNA sequence variation can influence gene activity in developing human brain

An international research collaboration has shed new light on how DNA sequence variation can influence gene activity in the developing human brain.

1 Dec 2015

Heptares announces strategic drug discovery collaboration with Pfizer

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation, announces that it has entered into a strategic drug discovery collaboration with Pfizer Inc. to research and develop potential new medicines directed at up to 10 G protein-coupled receptor (GPCR) targets across multiple therapeutic areas.

30 Nov 2015

UNC study reveals how specific schizophrenia symptoms linked to distinct brain circuits

Schizophrenia, a severe mental disorder affecting about one in 100 people, is notoriously difficult to diagnose and treat, in large part because it manifests differently in different people. A new study published today in Molecular Neuropsychiatry helps explain why.

25 Nov 2015

Mylan releases Clozapine Orally Disintegrating Tablets in U.S.

Mylan N.V. today announced the U.S. launch of Clozapine Orally Disintegrating Tablets, 25 mg and 100 mg, the generic version of Jazz Pharmaceutical's FazaClo.

24 Nov 2015

Interaction between two brain proteins has substantial effect on memory formation

In a new study that could have implications for future drug discovery efforts for a number of neurodegenerative diseases, scientists from the Florida campus of The Scripps Research Institute (TSRI) have found that the interaction between a pair of brain proteins has a substantial and previously unrecognized effect on memory formation.

20 Nov 2015

Structural differences in key brain region linked to hallucinations in people diagnosed with schizophrenia

People diagnosed with schizophrenia who are prone to hallucinations are likely to have structural differences in a key region of the brain compared to both healthy individuals and people diagnosed with schizophrenia who do not hallucinate, according to research published today.

17 Nov 2015

Study explores diabetes screening for patients with severe mental illness

A study just published in the Journal of the American Medical Association Internal Medicine examines diabetes screening for patients with severe mental illness, who are two to three times more likely to have type 2 diabetes than the general population. More than seven million Americans in the United States have severe mental illness, and there are many factors contributing to their increased risk of getting diabetes, including treatment with antipsychotic medication.

13 Nov 2015

Understanding how schizophrenia affects workings of the brain

Stem cells from adult schizophrenia patients form new proteins more slowly than those from healthy people, according to new research.

10 Nov 2015

Novel culturally-informed treatment benefits caregivers of people with schizophrenia

Schizophrenia is a chronic, severe and disabling psychiatric disorder that affects about one percent of the population in the United States. Approximately 60 percent of those suffering from this condition live with a relative. Despite the fact that that family interventions have shown to significantly improve outcomes for individuals with schizophrenia, only about seven percent of patients with this illness receive any family therapy.

6 Nov 2015

New study compares effectiveness of clozapine with standard antipsychotics in adults with schizophrenia

In real-world settings, patients with schizophrenia whose symptoms do not respond to standard antipsychotic medications have better outcomes if they are switched to clozapine instead of another standard antipsychotic. They have fewer hospitalizations, stay on the new medication longer, and are less likely to need to use additional antipsychotics.

6 Nov 2015

Computer algorithm may be useful in early diagnosis of schizophrenia

The opinion of a qualified professional is unlikely to be replaced by a computer algorithm for the diagnosis of schizophrenia. However, additional medical evidence based on such an algorithm might be useful in early diagnosis, according to work published in the International Journal of Intelligent Systems Technologies and Applications.

5 Nov 2015

Braeburn, Camurus announce FDA Fast Track designation for CAM2038 to treat opioid addiction

Braeburn Pharmaceuticals and Camurus announced today that the U.S. Food and Drug Administration granted Fast Track designation for the CAM2038 weekly and monthly buprenorphine subcutaneous injection products under development for the treatment of opioid addiction.

5 Nov 2015

General psychiatric support warranted in MS patients

Multiple sclerosis has a nonspecific effect on psychiatric morbidity, increasing the risk of all psychiatric disorders, shows a large population-based study.

3 Nov 2015

People with psychosis and addiction disorder may respond better to disorder-specific treatment

People with psychosis often develop an addiction disorder: almost one in two patients with schizophrenia are affected once during their lifetime. Patients with a dual diagnosis mostly have a poorer prognosis, and their disorder often becomes chronic.

31 Oct 2015

FAU, Max Planck ink new agreement to recruit and retain promising scientists

Florida Atlantic University, the Max Planck Florida Institute for Neuroscience and the Max Planck Society based in Germany, have signed an innovative agreement to facilitate a research and education program that will recruit promising scientists to MPFI and FAU.

30 Oct 2015

Pre-clinical study demonstrates positive effects of advanced prebiotic on neuro-inflammation, anxiety

Clasado Biosciences Limited, the producers and suppliers of the second generation prebiotic Bimuno(R) (B-GOS), a unique trans-galactooligosaccharide, and the Department of Psychiatry, University of Oxford, today announce the results of their latest pre-clinical study demonstrating a major role of the unique carbohydrate complex Bimuno against neuro-inflammation and anxiety.

28 Oct 2015

Schizophrenia News and Research

Latest Schizophrenia News and Research

UGA researchers identify biological markers for mental disorders

New drug therapies that target glutamate pathway may be effective for subgroups of patient with schizophrenia

Lawson scientists develop commercial imaging product for PET/MRI scanners

People exiting prison or jail get access to health services

DNA sequence variation can influence gene activity in developing human brain

Heptares announces strategic drug discovery collaboration with Pfizer

UNC study reveals how specific schizophrenia symptoms linked to distinct brain circuits

Mylan releases Clozapine Orally Disintegrating Tablets in U.S.

Interaction between two brain proteins has substantial effect on memory formation

Structural differences in key brain region linked to hallucinations in people diagnosed with schizophrenia

Study explores diabetes screening for patients with severe mental illness

Understanding how schizophrenia affects workings of the brain

Novel culturally-informed treatment benefits caregivers of people with schizophrenia

New study compares effectiveness of clozapine with standard antipsychotics in adults with schizophrenia

Computer algorithm may be useful in early diagnosis of schizophrenia

Braeburn, Camurus announce FDA Fast Track designation for CAM2038 to treat opioid addiction

General psychiatric support warranted in MS patients

People with psychosis and addiction disorder may respond better to disorder-specific treatment

FAU, Max Planck ink new agreement to recruit and retain promising scientists

Pre-clinical study demonstrates positive effects of advanced prebiotic on neuro-inflammation, anxiety

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Schizophrenia News and Research

Latest Schizophrenia News and Research

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Newsletters you may be interested in